Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ELUT 
Elutia Inc. (ELUT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: ELUT (1-star) is a SELL. SELL since 3 days. Simulated Profits (-43.10%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.5
1 Year Target Price $5.5
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -64.49% | Avg. Invested days 19 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 54.27M USD | Price to earnings Ratio - | 1Y Target Price 5.5 |
Price to earnings Ratio - | 1Y Target Price 5.5 | ||
Volume (30-day avg) 2 | Beta 0.89 | 52 Weeks Range 1.28 - 5.12 | Updated Date 09/14/2025 |
52 Weeks Range 1.28 - 5.12 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.43 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -90.01% | Operating Margin (TTM) -93.74% |
Management Effectiveness
Return on Assets (TTM) -37.27% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 74007035 | Price to Sales(TTM) 2.29 |
Enterprise Value 74007035 | Price to Sales(TTM) 2.29 | ||
Enterprise Value to Revenue 3.12 | Enterprise Value to EBITDA -3.32 | Shares Outstanding 38081900 | Shares Floating 15385269 |
Shares Outstanding 38081900 | Shares Floating 15385269 | ||
Percent Insiders 2.35 | Percent Institutions 70.65 |
Upturn AI SWOT
Elutia Inc.
Company Overview
History and Background
Elutia Inc., formerly known as SeaSpine Holdings Corporation, focuses on developing and commercializing orthobiologics and spinal implants to provide solutions for patients and surgeons. Founded in 2015, it has evolved to become a commercial-stage medical technology company.
Core Business Areas
- Orthobiologics: Development and commercialization of bone graft substitutes and biomaterials used in spinal fusion and other orthopedic procedures.
- Spinal Implants: Design, development, and commercialization of spinal implants and instrumentation for various spinal disorders.
Leadership and Structure
Daniel J. Chippon is the Chief Executive Officer. The company operates with a structure typical of medical device companies, encompassing R&D, manufacturing, sales, and marketing departments.
Top Products and Market Share
Key Offerings
- OsteoStrand Plus: A demineralized bone matrix (DBM) product designed for spinal fusion procedures. Market share data is not publicly available but it's a key revenue driver. Competitors include Medtronic (MDT), Stryker (SYK), and Zimmer Biomet (ZBH) in the DBM market.
- Marqibo: Marqibou00ae (vincristine sulfate liposome injection) is a prescription medicine used to treat adults with a rare form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative (Ph-) ALL. Competitors include generic vincristine products and other ALL treatments from companies like Amgen (AMGN) and Novartis (NVS).
Market Dynamics
Industry Overview
The orthobiologics and spinal implant market is driven by an aging population, increasing prevalence of spinal disorders, and advancements in medical technology. It's a competitive market with established players and ongoing innovation.
Positioning
Elutia Inc. competes by offering differentiated products and focusing on surgical solutions. It emphasizes innovative DBM offerings and strategic partnerships to gain market share.
Total Addressable Market (TAM)
The global spine surgery market is estimated to be around $10 billion. Elutia is positioned to capture a percentage of this TAM through its orthobiologics and spinal implant offerings, focusing on specific segments and applications.
Upturn SWOT Analysis
Strengths
- Innovative product portfolio
- Focus on specialized surgical solutions
- Experienced management team
- Strong distribution network
Weaknesses
- Smaller scale compared to industry giants
- Dependence on key products
- Limited financial resources relative to larger competitors
- History of losses
Opportunities
- Expanding into new geographic markets
- Developing new products and technologies
- Acquiring complementary businesses
- Increased adoption of minimally invasive surgery
Threats
- Intense competition from established players
- Price pressures from healthcare providers
- Regulatory changes
- Product liability risks
Competitors and Market Share
Key Competitors
- MDT
- SYK
- ZBH
Competitive Landscape
Elutia faces intense competition from larger, more established players with greater resources. Its competitive advantage lies in specialized products and surgical solutions. The remaining market share is distributed among smaller players.
Major Acquisitions
TCS
- Year: 2024
- Acquisition Price (USD millions): 20
- Strategic Rationale: Acquisition of TCS to extend the company's product range in orthobiologics
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by expansion of the product portfolio and increasing sales. Challenges have included achieving profitability.
Future Projections: Future projections depend on successful commercialization of new products and market penetration.
Recent Initiatives: Recent initiatives include new product launches, strategic partnerships, and expansion into new geographic markets.
Summary
Elutia Inc. is a medical technology company focused on orthobiologics and spinal implants, showing growth potential in a competitive market. Its innovative products and focused strategy are strengths, but it faces challenges from larger competitors and the need to achieve sustained profitability. Recent acquisitions look promising for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance can change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Elutia Inc.
Exchange NASDAQ | Headquaters Silver Spring, MD, United States | ||
IPO Launch date 2023-09-07 | Co-Founder, President, CEO & Director Dr. C. Randal Mills Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 51 | Website https://elutia.com |
Full time employees 51 | Website https://elutia.com | ||
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation and breast reconstruction in the United States. It operates in three segments: Device Protection, Women's Health, and Cardiovascular. The company offers EluPro, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators; and CanGaroo, which mitigates complications derived from implantable electronic devices and shortcomings of synthetic envelopes. It also provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material used to repair or reconstruct the peripheral vasculature. In addition, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction. It serves hospitals and healthcare facilities through its direct sales force, commercial partners, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.